In the AVALON cohort of relapsed/refractory AML treated with venetoclax plus hypomethylating agents, NPM1 and IDH1/2 mutations showed no significant impact on response or survival. These findings indicate that prognostic models for relapsed AML should consider treatment context rather than baseline mutation status.
NPM1 and IDH1/2 Mutations Show Limited Prognostic Impact in Relapsed/Refractory AML: Evidence From the AVALON Cohort / Vetro, C., Azzali, I., Petracci, E., Papayannidis, C., Eleuteri, E., Palumbo, F.E., Federico, V., Fracchiolla, N., Zappasodi, P., Martelli, M.P., Giannini, M.B., Brunetti, L., Palmieri, R., Nanni, J., Simonetti, G., Guolo, F., Minetto, P., Maurillo, L., Gigli, F., Billio, A., et al.. - In: HEMATOLOGICAL ONCOLOGY. - ISSN 1099-1069. - 44:1(2026). [10.1002/hon.70169]
NPM1 and IDH1/2 Mutations Show Limited Prognostic Impact in Relapsed/Refractory AML: Evidence From the AVALON Cohort
Brunetti, Lorenzo;
2026-01-01
Abstract
In the AVALON cohort of relapsed/refractory AML treated with venetoclax plus hypomethylating agents, NPM1 and IDH1/2 mutations showed no significant impact on response or survival. These findings indicate that prognostic models for relapsed AML should consider treatment context rather than baseline mutation status.| File | Dimensione | Formato | |
|---|---|---|---|
|
Vetro_NPM1-IDH1 2-Mutations-Show-Limited_2026.pdf
accesso aperto
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza d'uso:
Creative commons
Dimensione
476.38 kB
Formato
Adobe PDF
|
476.38 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
